Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$2.74
+5.4%
$2.55
$1.83
$7.48
$2.46B0.38.57 million shs26.97 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$39.53
-0.2%
$32.18
$16.16
$41.57
$1.61B0.88385,401 shs365,189 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$96.03
-0.2%
$93.99
$45.90
$106.52
$6.39B2.23543,802 shs409,289 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$33.67
+6.3%
$35.08
$6.76
$46.98
$3.04B0.361.76 million shs2.97 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+5.38%+13.69%+7.45%-3.52%-23.46%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-0.23%+0.25%+28.89%+61.68%+79.76%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-0.20%-3.75%-1.62%+54.96%+93.53%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+6.32%+6.62%+7.20%+8.09%+292.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$2.74
+5.4%
$2.55
$1.83
$7.48
$2.46B0.38.57 million shs26.97 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$39.53
-0.2%
$32.18
$16.16
$41.57
$1.61B0.88385,401 shs365,189 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$96.03
-0.2%
$93.99
$45.90
$106.52
$6.39B2.23543,802 shs409,289 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$33.67
+6.3%
$35.08
$6.76
$46.98
$3.04B0.361.76 million shs2.97 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+5.38%+13.69%+7.45%-3.52%-23.46%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-0.23%+0.25%+28.89%+61.68%+79.76%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-0.20%-3.75%-1.62%+54.96%+93.53%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+6.32%+6.62%+7.20%+8.09%+292.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
3.20
Buy$10.75292.34% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.86
Reduce$28.40-28.16% Downside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.07
Buy$101.575.77% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.18
Buy$46.3337.61% Upside

Current Analyst Ratings Breakdown

Latest PAHC, RYTM, SRRK, and IBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/15/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$51.00
9/10/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
9/8/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
8/29/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderperform$19.00 ➝ $27.00
8/28/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$34.00
8/28/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/26/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
8/21/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$50.00
8/14/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
8/7/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$80.00 ➝ $100.00
8/7/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$57.00 ➝ $45.00
(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$14.74M175.71N/AN/A($0.57) per share-4.81
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.24$3.26 per share12.12$7.05 per share5.61
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$156.29M40.81N/AN/A$0.35 per share274.37
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$3.94 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$1.1833.5018.821.183.73%32.14%6.89%11/5/2025 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)

Latest PAHC, RYTM, SRRK, and IBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q4 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.57+$0.05$0.42$362.24 million$378.70 million
8/6/2025Q2 2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.66-$0.98-$0.32-$0.98$0.11 millionN/A
8/5/2025Q2 2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.10-$0.10N/A-$0.10$21.95 million$26.43 million
8/5/2025Q2 2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.21%N/A40.68%N/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A

Latest PAHC, RYTM, SRRK, and IBRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.26%9/3/20259/3/20259/24/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
4.11
3.98
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.46
2.76
1.25
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
2.79
2.64
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.21
6.33
6.33

Institutional Ownership

CompanyInstitutional Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%

Insider Ownership

CompanyInsider Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
76.79%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
6.10%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
13.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
590945.26 million219.39 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.53 million20.24 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
14066.42 million62.37 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
14096.13 million83.34 millionOptionable

Recent News About These Companies

Scholar Rock initiated with an Outperform at Leerink

New MarketBeat Followers Over Time

Media Sentiment Over Time

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$2.74 +0.14 (+5.38%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$2.76 +0.02 (+0.91%)
As of 04:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$39.53 -0.09 (-0.23%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$40.04 +0.51 (+1.29%)
As of 09/15/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$96.03 -0.19 (-0.20%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$95.84 -0.20 (-0.20%)
As of 09/15/2025 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$33.67 +2.00 (+6.32%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$33.60 -0.08 (-0.22%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.